BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36307214)

  • 61. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
    Zhu H; Yang B; Liu J; Wu W; Ling Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
    Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
    Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
    Borges CS; Ferreira AF; Almeida VH; Gomes FG; Berzoti-Coelho MG; Cacemiro MDC; Nunes NS; Figueiredo-Pontes LL; Simões BP; Castro FA; Monteiro RQ
    Exp Hematol; 2018 Oct; 66():50-62. PubMed ID: 30076949
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
    Jones D; Kamel-Reid S; Bahler D; Dong H; Elenitoba-Johnson K; Press R; Quigley N; Rothberg P; Sabath D; Viswanatha D; Weck K; Zehnder J
    J Mol Diagn; 2009 Jan; 11(1):4-11. PubMed ID: 19095773
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.
    Dobrovic A; Trainor KJ; Morley AA
    Blood; 1988 Dec; 72(6):2063-5. PubMed ID: 3143430
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Platanias LC
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1():2-3. PubMed ID: 21208039
    [No Abstract]   [Full Text] [Related]  

  • 67. Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia.
    Berger R
    Leuk Lymphoma; 1993; 11 Suppl 1():235-7. PubMed ID: 8251902
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises.
    Ponzetto C; Guerrasio A; Rosso C; Avanzi G; Tassinari A; Zaccaria A; LoCoco F; Foa R; Basso G; Abate ML
    Br J Haematol; 1990 Sep; 76(1):39-44. PubMed ID: 2223647
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
    Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
    Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Near-hexaploid Ph-positive acute myeloid leukemia with major-BCR/ABL transcript.
    Iwama H; Ohyashiki K; Ohyashiki JH; Shimamoto T; Fujimura T; Kawakubo K; Kuriyama Y; Kodama A; Toyama K
    Cancer Genet Cytogenet; 1996 Jan; 86(1):61-4. PubMed ID: 8616789
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Minor breakpoint cluster region (m-BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report.
    Costello RT; Gabert J; Brunel V; Sainty D; Arnoulet C; Mozziconacci MJ; Camerlo J; Perret C; Gastaut JA; Bouabdallah R
    Br J Haematol; 1995 Oct; 91(2):428-30. PubMed ID: 8547089
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
    Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
    Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
    Sánchez R; Dorado S; Ruíz-Heredia Y; Martín-Muñoz A; Rosa-Rosa JM; Ribera J; García O; Jimenez-Ubieto A; Carreño-Tarragona G; Linares M; Rufián L; Juárez A; Carrillo J; Espino MJ; Cáceres M; Expósito S; Cuevas B; Vanegas R; Casado LF; Torrent A; Zamora L; Mercadal S; Coll R; Cervera M; Morgades M; Hernández-Rivas JÁ; Bravo P; Serí C; Anguita E; Barragán E; Sargas C; Ferrer-Marín F; Sánchez-Calero J; Sevilla J; Ruíz E; Villalón L; Del Mar Herráez M; Riaza R; Magro E; Steegman JL; Wang C; de Toledo P; García-Gutiérrez V; Ayala R; Ribera JM; Barrio S; Martínez-López J
    Sci Rep; 2022 Jul; 12(1):13057. PubMed ID: 35906470
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.
    Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J
    Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia.
    Keino D; Kinoshita A; Sudo A; Ohyama R; Mori T
    Pediatr Int; 2021 Jun; 63(6):728-729. PubMed ID: 34038034
    [No Abstract]   [Full Text] [Related]  

  • 80. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
    Konoplev S; Yin CC; Kornblau SM; Kantarjian HM; Konopleva M; Andreeff M; Lu G; Zuo Z; Luthra R; Medeiros LJ; Bueso-Ramos CE
    Leuk Lymphoma; 2013 Jan; 54(1):138-44. PubMed ID: 22691121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.